vTv Therapeutics Inc Sustainability Reports
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. Its clinical pipeline is primarily led by cadisegliatin, an adjunctive therapy being investigated for the treatment of type 1 diabetes.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300WQE5EI9R35SE66
FIGI: BBG009DT9XK8
7 reports from 2015 to 2024